Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG
Kazia Therapeutics (NASDAQ: KZIA) announced its participation in an Australian Medical Research Future Fund (MRFF) project focused on developing an AI-driven platform for treating diffuse midline glioma (DMG) and diffuse intrinsic pontine glioma (DIPG). The three-year initiative will establish DMG-ADAPTS, an AI-enabled clinical decision-making platform to optimize therapy sequencing for these aggressive pediatric brain cancers.
The project aims to integrate multiomics profiling with a therapeutic toolkit of twelve brain-penetrant molecules, including Kazia's investigational drug paxalisib, a dual PI3K/mTOR inhibitor. The initiative addresses DMG/DIPG, which accounts for up to 25% of childhood brain cancer deaths with median survival of less than one year. Kazia will provide paxalisib, which has shown encouraging activity in the PNOC 022 pediatric brain cancer trial.
Kazia Therapeutics (NASDAQ: KZIA) ha annunciato la propria partecipazione a un progetto australiano del Medical Research Future Fund (MRFF) mirato a sviluppare una piattaforma basata sull'Intelligenza Artificiale per trattare il glioma diffuso della linea mediana (DMG) e il glioblastoma pontino intrinseco diffuso (DIPG). L'iniziativa triennale istituisce DMG-ADAPTS, una piattaforma decisionale clinica potenziata dall'IA per ottimizzare la sequenza terapeutica in questi aggressivi tumori cerebrali pediatrici.
Il progetto intende integrare la profilazione multi-omics con un kit terapeutico di dodici molecole in grado di penetrare la barriera ematoencefalica, tra cui lo paxalisib, il farmaco sperimentale di Kazia, un inibitore duale PI3K/mTOR. L'iniziativa affronta DMG/DIPG, che rappresentano fino al 25% dei decessi per tumori cerebrali infantili con una sopravvivenza mediana inferiore a un anno. Kazia fornirà paxalisib, che ha mostrato attività incoraggiante nello studio pediatrico PNOC 022 sui tumori cerebrali infantili.
Kazia Therapeutics (NASDAQ: KZIA) anunció su participación en un proyecto del Australian Medical Research Future Fund (MRFF) destinado a desarrollar una plataforma impulsada por IA para tratar el glioma difuso de la línea media (DMG) y el glioma pontino intrínseco difuso (DIPG). La iniciativa de tres años establecerá DMG-ADAPTS, una plataforma de toma de decisiones clínicas potenciada por IA para optimizar la secuencia de terapias en estos agresivos tumores cerebrales pediátricos.
El proyecto busca integrar un perfil multi-ómica con un kit terapéutico de doce moléculas capaces de atravesar la barrera hematoencefálica, entre las que se incluye el fármaco en investigación de Kazia, paxalisib, un inhibidor dual de PI3K/mTOR. La iniciativa aborda DMG/DIPG, que representan hasta el 25% de las muertes por cáncer cerebral infantil y tienen una supervivencia mediana de menos de un año. Kazia proporcionará paxalisib, que ha mostrado actividad alentadora en el ensayo pediátrico PNOC 022 sobre cáncer cerebral infantil.
Kazia Therapeutics (NASDAQ: KZIA)가 호주 의학 연구 미래 기금(MRFF) 프로젝트에 참여해 확산형 중앙선 뇌종양(DMG)과 확산형 내뇌삼뇌종(DIPG) 치료를 위한 AI 기반 플랫폼 개발에 나섰다. 3년 간의 이니셔티브는 DMG-ADAPTS라는 AI 지원 임상 의사결정 플랫폼을 구축해 이들 공격적 소아 뇌암의 치료 순서를 최적화한다.
본 프로젝트는 다오믹 프로파일링과 12종의 뇌-침투 분자를 포함한 치료 도구 키트를 통합하는 것을 목표로 하며, Kazia의 신약 paxalisib도 포함된다. 이는 이중 PI3K/mTOR 억제제다. 이 이니셔티브는 평생환 DMG/DIPG를 다루며, 소아 뇌암 사망의 최대 25%를 차지하고 중앙 생존 기간이 1년 미만인 상황에 대응한다. Kazia는 paxalisib를 제공하고, PNOC 022 소아 뇌암 연구에서 우려되지 않은 활성을 보였다.
Kazia Therapeutics (NASDAQ: KZIA) a annoncé sa participation à un projet financé par le Medical Research Future Fund (MRFF) australien, axé sur le développement d’une plateforme pilotée par l’IA pour traiter le gliome diffus de la ligne médiane (DMG) et le gliome pontique diffus intrinsèque (DIPG). L’initiative triennale établira DMG-ADAPTS, une plateforme de décision clinique assistée par l’IA pour optimiser la séquence thérapeutique de ces cancers cérébraux pédiatriques agressifs.
Le projet vise à intégrer le profil multi-omique avec une trousse thérapeutique de douze molécules capables de traverser la barrière hémato-encéphalique, dont le médicament en développement paxalisib de Kazia, un inhibiteur dual PI3K/mTOR. L’initiative s’attaque au DMG/DIPG, qui représentaient jusqu’à 25% des décès par cancer cérébral chez l’enfant avec une survie médiane inférieure à un an. Kazia fournira paxalisib, qui a montré une activité encourageante dans l’essai pédiatrique PNOC 022 sur le cancer cérébral chez l’enfant.
Kazia Therapeutics (NASDAQ: KZIA) kündigte seine Teilnahme an einem australischen MRFF-Projekt (Medical Research Future Fund) an, das die Entwicklung einer KI-gesteuerten Plattform zur Behandlung von DMG (diffuse midline glioma) und DIPG (diffuse intrinsic pontine glioma) zum Ziel hat. Die dreijährige Initiative wird DMG-ADAPTS etablieren, eine KI-fähige klinische Entscheidungsunterstützung, um die Therapiesequenzierung bei diesen aggressiven pädiatrischen Hirntumoren zu optimieren.
Das Projekt zielt darauf ab, Multiomics-Profile mit einem therapeutischen Toolkit aus zwölf Molekülen zu integrieren, darunter Kazias experimentelles Medikament paxalisib, ein doppelter PI3K/mTOR-Inhibitor. Die Initiative behandelt DMG/DIPG, die bis zu 25% der Todesfälle bei kindlichem Hirntumor ausmachen und eine mediale Überlebenszeit von weniger als einem Jahr aufweisen. Kazia wird paxalisib bereitstellen, das positive Aktivität im PNOC 022-KINDERHIRNTUMOR-Studie gezeigt hat.
Kazia Therapeutics (NASDAQ: KZIA) أعلنت عن مشاركتها في مشروع تموله صندوق البحث الطبي المستقبلي الأسترالي MRFF يركز على تطوير منصة مدعومة بالذكاء الاصطناعي لعلاج الورم الدماغي DMG وDIPG. ستنشئ المبادرة لمدة ثلاث سنوات DMG-ADAPTS، وهي منصة اتخاذ قرارات سريرية معززة بالذكاء الاصطناعي لتحسين تتابع العلاج لهذه السرطانات الدماغية pediatricية العدوانية.
يهدف المشروع إلى دمج ملف تعريف متعدد-omics مع مجموعة علاجية من twelve جزيئات قادرة على عبور الحاجز الدموي الدماغي، من ضمنها دواء Kazia التجريبي paxalisib، مثبط ثنائي لـ PI3K/mTOR. تتناول المبادرة DMG/DIPG، والتي تمثل حتى 25% من وفيات سرطان الدماغ لدى الأطفال مع بقاء الوسيط البقائي أقل من عام. ستوفر Kazia paxalisib، الذي أظهر نشاطاً مشجّعاً في تجربة PNOC 022 لسرطان الدماغ لدى الأطفال.
Kazia Therapeutics (NASDAQ: KZIA) 宣布参与澳大利亚医学研究未来基金（MRFF）的一项项目，专注于开发用于治疗弥散中线胶质瘤（DMG）和弥散性特发性桥脑胶质瘤（DIPG）的人工智能驱动平台。为期三年的计划将建立DMG-ADAPTS，一个由AI支持的临床决策制定平台，以优化这些高侵袭性儿童脑肿瘤的治疗序列。
该项目旨在将多组学分析与含有十二种可穿越血脑屏障分子的治疗工具包整合，其中包括 Kazia 的在研药物paxalisib，是一种双PI3K/mTOR抑制剂。该计划针对 DMG/DIPG，这类疾病在儿童脑瘤死亡中占比高达25%，中位生存期不足一年。Kazia 将提供 paxalisib，该药在 PNOC 022 儿童脑瘤试验中显示出令人鼓舞的活性。
- None.
- Current DMG/DIPG treatments show limited durable responses due to rapid resistance
- Project outcomes and clinical benefits remain uncertain
Insights
Kazia's participation in AI-driven pediatric brain cancer project represents progress in pipeline development but offers no immediate revenue impact.
Kazia Therapeutics is contributing its investigational drug paxalisib to a significant Australian research initiative focused on developing AI-driven therapeutic strategies for diffuse midline glioma (DMG), including the devastating childhood brain cancer DIPG. This collaboration with Australian researchers leverages a fully funded
This research partnership has strategic importance for Kazia's pipeline development. DMG/DIPG is an ultra-rare but deadly pediatric cancer, responsible for up to
From a pipeline perspective, this initiative builds upon existing evidence for paxalisib in pediatric brain cancers, with the company noting "encouraging activity" in the ongoing PNOC 022 study. The AI platform being developed could potentially accelerate clinical decision-making and improve patient outcomes by identifying the optimal sequencing and timing of therapies.
This represents a cost-effective approach for Kazia, as they're providing drug supply while the Australian MRFF covers research funding. While this collaboration won't generate near-term revenue, it expands paxalisib's potential applications and could strengthen its clinical profile if successful. For a clinical-stage biotech company like Kazia, building evidence for their lead asset across multiple indications enhances long-term value despite not impacting immediate financial results.
Under this three-year initiative, a consortium of leading researchers will establish DMG-ADAPTS, an advanced AI-enabled clinical decision-making platform designed to optimize sequencing and timing of targeted therapies for diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG). Kazia will provide its investigational drug paxalisib, a brain-penetrant, dual PI3K/mTOR inhibitor, to support the study.
Project Overview
DMG/DIPG represents one of the most devastating pediatric cancers, accounting for up to
The MRFF-funded project aims to address this challenge by:
- Developing DMG-ADAPTS, a cloud-based AI platform integrating multiomics, tumor, CSF, and blood profiling to guide individualized, adaptive therapy decisions in real time.
- Testing a therapeutic toolkit of twelve brain-penetrant small molecules (including paxalisib) and immunotherapies across preclinical patient-derived models.
- Establishing non-invasive biomarkers to anticipate resistance and inform timely therapeutic transitions.
Lead investigator, University of Newcastle Professor of Paediatric Haematology and Oncology Matt Dun, of HMRI's Precision Medicine Research Program, said "Our extensive work, alongside that of the international community, has identified key genetic and adaptive vulnerabilities in DMG. Therapeutics such as paxalisib represent an important addition to the treatment toolkit, ensuring patients have every chance at long-term survival. We are delighted to partner with Kazia to define where paxalisib best fits within our therapeutic strategy".
Kazia's Role
Kazia will contribute paxalisib, already under evaluation in multiple clinical studies for both adult and pediatric brain cancers. Notably, positive signals have been reported in the PNOC 022 study, a multi-arm pediatric brain cancer trial where paxalisib has shown encouraging activity.
"Our participation in this MRFF project underscores Kazia's continued commitment to finding innovative solutions for children facing DIPG and DMG," said Dr. John Friend, Chief Executive Officer of Kazia Therapeutics. "By integrating cutting-edge AI with precision therapies such as paxalisib, this initiative has the potential to revolutionize how these aggressive tumors are managed. We are proud to provide drug supply support in this cost-conscious collaboration that leverages global research excellence."
For investor and media, please contact Alex Star, Managing Director LifeSci Advisors LLC, Astarr@lifesciadvisors.com, +1-201-786-8795.
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in
Forward-Looking Statements
This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as "may," "will," "estimate," "future," "forward," "anticipate," or other similar words. Any statement describing Kazia's future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward looking statements, including, but not limited to, statements regarding: the timing for results and data related to Kazia's clinical and preclinical trials, Kazia's strategy and plans with respect to its paxalisib program, the potential benefits of paxalisib as an investigational PI3K/mTOR inhibitor, timing for any regulatory submissions or discussions with regulatory agencies, the potential market opportunity for paxalisib and Kazia's intent and efforts to regain and/or maintain compliance with the applicable Nasdaq continued listing requirements and standards. Such statements are based on Kazia's current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties associated with clinical and preclinical trials and product development, including the risk that interim or early data may not be consistent with final data, risks related to regulatory approvals, risks related to the impact of global economic conditions, and risks related to Kazia's ability to regain and/or maintain compliance with the applicable Nasdaq continued listing requirements and standards. These and other risks and uncertainties are described more fully in Kazia's Annual Report, filed on form 20-F with the SEC, and in subsequent filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.
This announcement was authorized for release by Dr John Friend, CEO
View original content:https://www.prnewswire.com/news-releases/kazia-therapeutics-supports-australian-mrff-funded-project-developing-ai-driven-sequential-therapy-strategy-for-dipgdmg-302572508.html
SOURCE Kazia Therapeutics Limited
FAQ
What is Kazia Therapeutics' role in the MRFF-funded DMG/DIPG research project?
What is the goal of the DMG-ADAPTS platform being developed with KZIA's support?
How severe is the DMG/DIPG condition that KZIA's research targets?
What progress has KZIA's paxalisib shown in treating pediatric brain cancers?
How long will the MRFF-funded project involving KZIA last?
